Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 205 citing articles:

Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective
Vaishali R. Moulton, Abel Suárez‐Fueyo, Esra Meidan, et al.
Trends in Molecular Medicine (2017) Vol. 23, Iss. 7, pp. 615-635
Open Access | Times Cited: 406
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
Kenneth F. Baker, John D. Isaacs
Annals of the Rheumatic Diseases (2017) Vol. 77, Iss. 2, pp. 175-187
Closed Access | Times Cited: 337
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
William Stohl, Andreas Schwarting, Masato Okada, et al.
Arthritis & Rheumatology (2017) Vol. 69, Iss. 5, pp. 1016-1027
Open Access | Times Cited: 332
Targeting B Cells and Plasma Cells in Autoimmune Diseases
Katharina Hofmann, Ann‐Katrin Clauder, Rudolf A. Manz
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 235
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
David Isenberg, Michelle Petri, Kenneth Kalunian, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 2, pp. 323-331
Open Access | Times Cited: 211
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
Eileen T. Samy, Stephen Wax, Bertrand Huard, et al.
International Reviews of Immunology (2017) Vol. 36, Iss. 1, pp. 3-19
Open Access | Times Cited: 180
Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New
Fabio Basta, Federica Fasola, Konstantinos Triantafyllias, et al.
Rheumatology and Therapy (2020) Vol. 7, Iss. 3, pp. 433-446
Open Access | Times Cited: 171
Targeting co-stimulatory molecules in autoimmune disease
Natalie M. Edner, Gianluca Carlesso, James S. Rush, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 12, pp. 860-883
Closed Access | Times Cited: 167
B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE)
Tamara Möckel, Fabio Basta, Julia Weinmann‐Menke, et al.
Autoimmunity Reviews (2020) Vol. 20, Iss. 2, pp. 102736-102736
Closed Access | Times Cited: 146
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation
Agner R. Parra Sánchez, Alexandre E. Voskuyl, Ronald van Vollenhoven
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 3, pp. 146-157
Closed Access | Times Cited: 83
Advances in the management of systemic lupus erythematosus
Eric F. Morand, Ruth Fernandez‐Ruiz, Ashira Blazer, et al.
BMJ (2023), pp. e073980-e073980
Open Access | Times Cited: 42
B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments
Desmond Y. H. Yap, Tak Mao Chan
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6231-6231
Open Access | Times Cited: 141
New therapies for systemic lupus erythematosus — past imperfect, future tense
Gráinne Murphy, David Isenberg
Nature Reviews Rheumatology (2019) Vol. 15, Iss. 7, pp. 403-412
Open Access | Times Cited: 134
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill, William Shanahan, Morton Scheinberg, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 6, pp. 883-889
Open Access | Times Cited: 130
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
Daniel J. Wallace, Vibeke Strand, Joan T. Merrill, et al.
Annals of the Rheumatic Diseases (2016) Vol. 76, Iss. 3, pp. 534-542
Open Access | Times Cited: 116
Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity
Diogo Jesús, Ana Matos, Carla Henriques, et al.
Annals of the Rheumatic Diseases (2019) Vol. 78, Iss. 3, pp. 365-371
Open Access | Times Cited: 112
The BAFFling effects of rituximab in lupus: danger ahead?
Michael R. Ehrenstein, Charlotte Wing
Nature Reviews Rheumatology (2016) Vol. 12, Iss. 6, pp. 367-372
Open Access | Times Cited: 102
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019
Kevin Winthrop, Michael E. Weinblatt, Joan M. Bathon, et al.
Annals of the Rheumatic Diseases (2019) Vol. 79, Iss. 1, pp. 88-93
Open Access | Times Cited: 96
Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments
Zahi Touma, Dafna D. Gladman
Lupus Science & Medicine (2017) Vol. 4, Iss. 1, pp. e000239-e000239
Open Access | Times Cited: 95
Mesenchymal Stem Cell Therapy: Hope for Patients With Systemic Lupus Erythematosus
Aifen Li, Fengbiao Guo, Quanren Pan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 81
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Kathryn M. Kingsmore, Amrie C. Grammer, Peter E. Lipsky
Nature Reviews Rheumatology (2019) Vol. 16, Iss. 1, pp. 32-52
Closed Access | Times Cited: 79
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Richard Furie, Ian N Bruce, Thomas Dörner, et al.
Lara D. Veeken (2021) Vol. 60, Iss. 11, pp. 5397-5407
Open Access | Times Cited: 76
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Raj Tummala, Gabriel Abreu, Lilia Pineda, et al.
Lupus Science & Medicine (2021) Vol. 8, Iss. 1, pp. e000464-e000464
Open Access | Times Cited: 75
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Di Wu, Jing Li, Dong Xu, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 4, pp. 475-487
Open Access | Times Cited: 41
Current treatment of systemic lupus erythematosus: a clinician's perspective
Katarzyna Pawlak‐Buś, Wiktor Schmidt, Dudziec Ewa, et al.
Rheumatology International (2023) Vol. 43, Iss. 8, pp. 1395-1407
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top